BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CEA-Leti Release: CLINATEC Chairman Alim-Louis Benabid Honored by The Michael J. Fox Foundation for Pioneering Work in Treating Parkinson's Disease


7/8/2013 10:27:49 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GRENOBLE, France--(BUSINESS WIRE)--CEA-Leti today announced that Prof. Alim-Louis Benabid, chairman of the board of CLINATEC, has received the Robert A. Pritzker Prize for Leadership in Parkinson’s Research from the Michael J. Fox Foundation for his pioneering work on treating Parkinson’s disease (PD). The prize, and a $100,000 award (€75,624), recognizes Benabid’s contributions to developing innovative surgical methods for treating severe PD. Benabid invented deep brain stimulation (DBS), a standard method of treating advanced PD, in which electrodes placed in the patients’ brain create pulses that eliminate tremors associated with the disease. "Professor Benabid's contributions to the field of Parkinson's disease research, and to improving lives of those living with the disease, are well-documented," said Todd Sherer, CEO of the Michael J. Fox Foundation. "Today, deep brain stimulation remains a viable option for many with PD, and one that can offer life-altering results. Since his groundbreaking work with DBS, Prof. Benabid has refused to rest on his laurels, but instead, he has remained committed to improving on existing treatments for PD. We are proud to recognize him for a lifetime of devotion to this goal."

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES